TSO3 CEO to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston

Ticker Symbol: TOS/TSX
Shares Outstanding: 65,888,182

QUEBEC CITY, Aug. 13, 2012 /CNW Telbec/ - TSO₃ Inc. ("TSO₃") (TSX: TOS) an innovator in low temperature sterilization technology for medical devices in healthcare settings, announced today that Mr. R.M. (Ric) Rumble, CEO of TSO₃, will be giving a corporate presentation at 13:30 (ET) tomorrow, August 14 at the Canaccord Genuity 32^nd Annual Growth Conference.

TSO₃ will offer a live audio webcast of its presentation, as well as an archived replay, which may be accessed at the following address: http://wsw.com/webcast/canaccord6/tos/

Conference Details:
2012 Canaccord Genuity Growth Conference
August 14-16, 2012
Intercontinental Boston Hotel, Boston, Massachusetts
More information: http://www.canaccordgenuity.com

About TSO₃

TSO₃, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO₃ designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.

For more information about TSO₃, visit the Corporation's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO₃ relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO₃) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO₃ to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

SOURCE: TSO3 INC.

Source: TSO₃ Inc.

Information:
Caroline Côté
Director - Investor and Business Relations
[phone], Ext. 237
Email: [email protected]